FindMyKOL
Clinical trialNCT06263543RecruitingPhase 2Interventional

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

SponsorReshma L. Mahtani, D.O.Enrollment75Breast CancerMetastatic Breast CancerAdvanced Breast CancerHormone-receptor-positive Breast CancerHuman Epidermal Growth Factor 2 Low Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this research study is to see if the medication sacituzumab govitecan (SG) is effective at the currently approved dose and schedule in people who have previously received trastuzumab deruxtecan (T-DXd) for the treatment of metastatic, hormone receptor positive (HR+)/human epidermal growth factor 2 low (HER2 low) breast cancer. Although SG is approved to treat metastatic HR+/HER2 negative breast cancer, the aim of this study is to determine if SG is still effective specifically in people who have already received T-DXd.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

  • Reshma L Mahtani, D.O.

    Baptist Health Herbert Wertheim Cancer Institute

    Principal Investigator
    clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Baptist Health Herbert Wertheim Cancer Institute

    Miami, Florida, United States

    Recruiting
  • Winship Cancer Institute at Emory University

    Atlanta, Georgia, United States

    Recruiting
  • University of Kansas Medical Center

    Fairway, Kansas, United States

    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Sacituzumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
17 Jun 2024
Primary completion
30 Jun 2028
Completion
31 Dec 2028
Last update posted
12 Aug 2026
Registered enrollment
75
Registry id
NCT06263543
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.